The crisis at pharmaceutical packaging specialist Gerresheimer has entered a critical new phase, defined by a looming legal battle and a precarious financial lifeline. While the company secured temporary breathing room from its lenders, shareholder advocates are now preparing damage claims against its former leadership, adding a significant new layer of risk.

The German Association for the Protection of Shareholders (DSW) has commissioned a legal opinion to examine claims for compensation against former CEO Dietmar Siemssen and former CFO Bernd Metzner, as well as the supervisory board and its audit committee. The focus extends beyond confirmed accounting irregularities to include valuation questions surrounding goodwill assets worth approximately €676 million. "The clearer the claims become, the more likely it is that a litigation financier will get involved," stated DSW Managing Director Marc Tüngler, calling on affected investors to coordinate.

This legal threat stems from a core scandal involving so-called bill-and-hold agreements. An independent law firm confirmed Gerresheimer systematically invoiced customers for goods before shipping them, booking revenue prematurely in violation of IFRS rules. These violations impacted €35 million in revenue and €24 million in adjusted EBITDA. The fallout has frozen the company's entire reporting calendar. The Q1 2026 report, originally scheduled for April 16, is postponed, and the Annual General Meeting set for June 3 is cancelled. The next fixed date is the half-year report on July 14, 2026.

Concurrently, Gerresheimer is navigating severe financial constraints. The company has breached contractual reporting obligations, placing it in technical default with its creditors. However, it recently won a crucial reprieve: 96% of its bondholders agreed to extend the deadline for submitting the audited 2025 financial statements to September 30, 2026. Banking partners followed suit, also suspending key covenant tests related to leverage ratios through Q3 2026. The total volume of the bonds is €870 million. Management aims to deliver the audited report by June 2026, ahead of the new contractual deadline, pending the outcome of internal investigations into 2024 and 2025 business practices.

To shore up its capital structure, Gerresheimer has initiated a sale process for its profitable US subsidiary, Centor Inc., which specializes in packaging systems for prescription drugs. Morgan Stanley is advising on the sale, which has already attracted interest from a double-digit number of potential buyers. The company targets a transaction closure within this year. Centor is a key asset, carrying a book value of €292 million at the end of 2024.

The cumulative damage is starkly reflected in the share price. The stock has fallen approximately 36% since the start of the year and is down about 73% from its 52-week high of €64.40, currently trading around €17.66. The accounting failure also triggered an automatic removal from the SDAX index on April 10, 2026, after the company missed a four-month reporting deadline, forcing index-tracking funds to sell and creating technical downward pressure.

Further financial pain comes from planned non-cash impairments of €220 to €240 million, primarily related to technology projects at subsidiary Sensile Medical AG and assets at Gerresheimer Moulded Glass Chicago Inc. The company's revenue guidance for 2026 of €2.3 to €2.4 billion remains explicitly conditional on successful outcomes from the ongoing bank negotiations and the resolution of objections from German financial regulator BaFin.

Despite the turmoil, some institutional investors see opportunity at depressed prices. CastleKnight and Deka Investment have recently reported new stakes. Yet, without an audited balance sheet, any fundamental valuation of the company—or serious takeover speculation—remains impossible. The path forward now hinges on two imminent tests: finalizing the Centor sale and delivering the long-delayed audited financials by June. The half-year report in July will reveal if Gerresheimer can finally begin to clear the paralyzing information logjam.

Ad

Fresh Gerresheimer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.